News | July 10, 2014

480 Biomedical Awarded $1 Million Phase II NHLBI Contract to Advance Bioresorbable Scaffold Technology

July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and Blood Institute (NHLBI) to continue the development of a bioresorbable, self-expanding scaffold to treat pediatric pulmonary artery stenosis (PAS). The product aims to address the serious challenges in treating cardiovascular stenosis in children with growing blood vessels. The scaffold’s unique design has the strength of a balloon-expandable metal stent to keep vessels open for an extended period before safely resorbing. The scaffold can also be delivered through a small catheter, which is essential for treating a pediatric population. This latest $1 million round of funding will be used to further refine the design of the product and conduct preclinical testing.

Metal stents, which are currently used in these procedures, are not well suited for pediatric patients since they become restrictive as the patient grows. Pediatric patients that are treated with metal stents often require re-intervention or surgical removal of the stent to address arterial obstruction and to reestablish blood flow.

“There has not been a significant advance in this area in decades,” said Robert J. Lederman, M.D., senior investigator and chief of cardiovascular intervention, division of intramural research, NHLBI. “480 Biomedical is the right team to develop a product that will help solve the critical challenge facing pediatric cardiologists in treating pulmonary artery stenosis. We are excited about the progress made to date and the overall important effort underway to improve care for the smallest, most vulnerable cardiology patients, who deserve our attention.”

480 Biomedical has developed a prototype of the pediatric scaffold that demonstrates acute strength similar to a metal stent, tissue absorption over the course of approximately one year, and minimally invasive delivery of the scaffold through a small flexible catheter. Under the provisions of the NHLBI contract, 480 Biomedical is responsible for the overall development of the pediatric scaffold and the NHLBI will undertake clinical study of the product.

“Tackling this complex problem successfully will have an important impact on the clinical approach to treating PAS, and potentially other pediatric cardiac and pulmonary conditions,” said Maria Palasis, Ph.D., executive vice president and chief technology officer, 480 Biomedical. “Our team is applying extensive knowledge and expertise from the development of our Stanza scaffold technology for peripheral vascular disease to transform care and improve outcomes for these young patients.”

The Stanza scaffold technology combines biocompatible materials with innovative engineering for optimal balance of radial force, flexibility and bioresorbability. This proprietary scaffold is also ideal for controlled delivery of drug for several months. It supports the lumen while healing occurs, resorbing in about a year. The strength of the scaffold, followed by its resorption, provides the benefits of scaffolding while avoiding the potential downsides of a permanent implant, including irritation, fracture and difficulty of retreatment.

For more information: www.480biomedical.com, www.nhlbi.nih.gov

Related Content

Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
BVS, Absorb stent, bioresorbable scaffold, ABSORB III data, ABSORB III results
Feature | Stents Bioresorbable| March 21, 2017 | Dave Fornell
March 21, 2017 — In the late-breaking ABSORB III Trial two year results presented at the American College of Cardiolo
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Absorb, bioresorbable stent, BVS, top cardiology story of 2016

The FDA clearance of the first fully bioresorbable stent, the Abbott Absorb BVS, was by far the top story of 2016. Readers clearly had a massive interest in this technology based on their page views of this article, related bioresorbable stent content and a video interviews with key ABSORB study investigators.

Feature | December 21, 2016 | Dave Fornell
The Diagnostic and Interventional Cardiology (DAIC) website had a record year in 2016, breaking 1 million pa
Sponsored Content | Videos | Stents Bioresorbable| November 09, 2016
Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirb
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Fortitude bioresorbable stent

The Fortitude sirolimus-eluting bioresorbable stent.

 

News | Stents Bioresorbable| November 07, 2016
The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3 in Washington, D.C...
Overlay Init